Lenstatin? LLC Announces the Post-Vitrectomy Lenstatin? Study - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Lenstatin? LLC Announces the Post-Vitrectomy Lenstatin? Study A Randomized Double-Blind Human Clinical Trial Evaluating the Efficacy of Lenstatin in Inhibiting Cataract Formation and Progression After Pars Plana Vitrectomy


Lenstatin™ LLC Announces the Post-Vitrectomy Lenstatin™ Study

A Randomized Double-Blind Human Clinical Trial Evaluating the Efficacy of Lenstatin in Inhibiting Cataract Formation and Progression After Pars Plana Vitrectomy

PR Newswire

WILMINGTON, N.C., May 22, 2014 /PRNewswire/ -- There are conflicting scientific reports on the effectiveness of nutritional antioxidants in preventing or slowing the growth of age related cataracts, despite extensive basic science research indicating that oxidative damage to the human lens is a common underlying etiologic factor in cataractogenesis. One reported review of nine clinical trials involving over 117,000 patients suggested that beta-carotene, Vitamin E, and Vitamin C had no effect in preventing or slowing the progression of age-related cataract.

Lenstatin(TM) LLC announces the post-vitrectomy Lenstatin(TM) study: a randomized double-blind human clinical trial evaluating
               the efficacy of Lenstatin(TM) in inhibiting cataract formation and progression after pars plana vitrectomy.

Conversely, a randomized trial of over 14,000 US male physicians indicated that long-term daily multivitamin use modestly decreased the risk of cataract.

Lenstatin ™ is the world's first proprietary formulated nutritional supplement containing 11 micronutrients and anti-oxidants which are targeted to support the health of the human crystalline lens in patients with early cataracts.

According to Principal Investigator Scott W. Tunis MD FACS, "Cataract formation is a well-recognized complication of pars plana vitrectomy surgery, with the reported incidence of developing clinically significant cataract within two years after the procedure as high as 80%. Cataracts occurring after pars plana vitrectomy are commonly of the nuclear type, similar in morphology to age-related cataracts. This study allows us to evaluate the efficacy of Lenstatin™ in preventing or inhibiting the progression nuclear cataracts over a significantly shorter interval of time than would be necessary for age-related cataracts, which may take decades to develop."

Subjects will be randomly allocated to treatment with Lenstatin™ or Placebo with treatment group identity concealed from the Investigator, participants, and data collectors. Cataract formation and progression will be compared between treatment groups using the Oculus Pentacam Nuclear Staging Program (PNS) which has been shown to provide an immediate, quantitative, and examiner-independent measurement of lens density which correlates reliably with LOCS III cataract grade. The study is registered with www.clinicaltrials.gov and is being conducted under IRB supervision.

Visit Lenstatin.com to learn more.

Photo - http://photos.prnewswire.com/prnh/20140522/90574

SOURCE Lenstatin LLC

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here